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| INTRODUCTION
One of the most debated challenges of management of patients with venous thromboembolism (VTE) is the determination of the optimal duration of anticoagulation. As the risk of recurrent VTE is low after VTE associated with a major transient risk factor (eg, major surgery), current international guidelines recommend cessation of anticoagulant treatment after a minimum of 3 months. [1] [2] [3] [4] [5] On the other hand, patients with active cancer-associated VTE are candidates for extended anticoagulation in light of the substantial risk for recurrence.
However, the benefit of long-term anticoagulation is not fully established because of their concomitant high risk of bleeding.
1,2,6-8
The risk of recurrent VTE after anticoagulant discontinuation in patients with unprovoked VTE is reported to be high as well, with a 20-year rate of 30% to 50%. 3, 9, 10 Therefore, indefinite anticoagulant therapy after unprovoked VTE events is usually recommended, with the important exception of patients at high risk of bleeding. 1, 2 Although several risk prediction scores have been developed over the years for the identification of VTE patients at a high risk of bleeding, these tools present major limitations for use in routine practice, including the fact that they were derived from observational data of moderate quality, lack proper validation in adequately powered studies with adjudication of the events, and mostly focus on the acute phase of treatment with vitamin K antagonist (VKA) anticoagulation, rather than long-term treatment with DOACs. Furthermore, many of these scores were originally derived using data of patients outside of VTE populations (eg, atrial fibrillation, cardiac surgery) and may thereby not be completely relevant in the context of the VTE patients. 11 Most importantly, these score variables largely overlap with predictors of VTE recurrence demonstrating that these scores are not useful for decision making regarding optimal duration of anticoagulation in unprovoked VTE patients.
In a previous study, we derived VTE-BLEED, a simple 6-variable risk score designed to predict major bleeding in patients with VTE on stable, long-term anticoagulation (Table 1) . 12 This score was found to identify VTE patients at a 3-to 5-fold increased risk of bleeding during therapy with either VKA, direct thrombin inhibitors, or direct factor Xa inhibitors, both in a clinical trial setting and in a large practice-based cohort. [12] [13] [14] [15] The score demonstrated good predictive ability, with the C-statistic reaching 0.78. That being said, it is currently unknown whether implementation of the VTE-BLEED into clinical practice will present physicians with a confounding effect between risk of bleeding and risk of recurrence similar to that described above. In light of this question, we performed a post hoc analysis of the PADIS-PE trial 16 to assess and compare the incidence embolism (PE) initially treated during 6 months to receive an additional 18-month of warfarin vs. placebo. The primary outcome of this analysis was recurrent VTE during 2-year follow-up after anticoagulant discontinuation, that is, after the initial 6-month treatment in the placebo arm and after 24 months of anticoagulation in the active treatment arm. This rate, adjusted for study treatment allocation, was compared between patients in the high-vs. low-risk VTE-BLEED group. 
Results

Conclusion:
In this study, patients with unprovoked PE classified at high risk of major bleeding by VTE-BLEED did not have a higher incidence of recurrent VTE after cessation of anticoagulant therapy, supporting the potential yield of the score for making management decisions on the optimal duration of anticoagulant therapy.
K E Y W O R D S
anticoagulation therapy, bleeding, prediction score, recurrence, venous thromboembolism of recurrent VTE after discontinuation of anticoagulant treatment in patients in the high-vs. low-risk VTE-BLEED category in order to determine whether there was an association between risk classification according to the VTE-BLEED and VTE recurrence in these patients.
| METHODS
| Study setting and patients
The design of the PADIS-PE study and patients' selection criteria are detailed in the original publication. 16 In short, PADIS-PE was a randomized, double-blind, placebo-controlled trial in patients with a first unprovoked pulmonary embolism (PE). The trial aimed at determining the benefits and harms of 6 vs. 24 months of anticoagulation with VKA. Patients were randomized after an initial 6-month course of anticoagulants to either continuation of anticoagulant treatment or placebo. The primary outcome was the composite of recurrent VTE or major bleeding at 18 months after randomization. One of the secondary outcomes was the incidence of the primary outcome after a follow-up period of 42 months.
Symptomatic recurrent VTE was diagnosed upon clinical suspicion and objective confirmation by ultrasonography, ventilation-perfusion lung scanning, spiral computed tomographic angiography, pulmonary angiography, or autopsy, and in the event of a sudden death for which no other cause could be identified. 17 Definition of major bleeding was based on the ISTH recommendations. 18 All outcomes were adjudicated by an independent central adjudication committee. 16 For the current analysis, we considered all patients with complete baseline data (complete case analysis) in whom VTE-BLEED could be calculated.
| VTE-BLEED
The 6-variable VTE-BLEED score (Table 1) 
| Study aim
The aim of the current analysis was to assess and compare the inci- 
| Statistical analysis
For the presentation of the baseline characteristics, continuous variables are described with means and standard deviation, and categorical variables are presented as proportions (n/N) and percentage (%). The absolute number and cumulative incidence of the primary and secondary outcomes are presented with corresponding 95%
confidence intervals (CIs). A Cox regression model using VTE-BLEED and treatment group as covariates was applied to compare the incidence of recurrent VTE in the 2 VTE-BLEED risk categories, adjusted for study treatment allocation. Statistical analyses were performed using SAS V9.4 software (SAS Institute, Cary, NC).
| RESULTS
| Patients
From all 374 patients included in the original study, 3 withdrew informed consent, and data for calculation of the VTE-BLEED score were missing in 63 (16%; see characteristics in Table S1 ): data on the presence of anemia in 44 patients, on hypertension in 8 patients, The estimated glomerular filtration rate (eGRF) <60 mL/min defined the presence of renal dysfunction: eGRF was calculated at baseline with the Cockcroft-Gault formula, which includes serum creatinine, age, and body weight.
on renal dysfunction in 2, and on anemia plus renal dysfunction in 9 patients. Those patients were excluded. The mean age of the 308 (82.4%) patients left for analysis was 58.7 years (±18.0), 164 (53.2%) patients were women, 21 (6.8%) patients had an estimated creatinine clearance (Cockcroft) <50 mL/min and 13 (4.2%) patients had a history of cancer (Table 2 ). Figure 1 ). All episodes were unexplained sudden deaths considered to be fatal PE by the adjudication committee.
| VTE-BLEED
| DISCUSSION
Our main finding is that, after anticoagulant discontinuation, patients with unprovoked VTE in the VTE-BLEED high-risk category (29% of all patients) did not have a higher risk of developing recurrent VTE than patients in the low-risk VTE-BLEED category (adjusted HR, Furthermore, in contrast with other currently available bleeding risk scores, the VTE-BLEED was evaluated and validated both in nonselected VTE patients and in patients with unprovoked VTE, as well as for all currently available classes of oral anticoagulants. [12] [13] [14] [19] [20] [21] [22] [23] [24] [25] [26] [27] Additionally, the binary categorization used in the VTE-BLEED limits the commonly encountered ambiguity surrounding clinical Treatment of pulmonary embolism prior to randomization Strengths of this analysis include the randomized design of the study as well as the blinded adjudication of primary and secondary end points. The main limitation of our study rests in its post hoc nature, resulting in a relatively high proportion of patients with missing data for the calculation of the VTE-BLEED score, potentially introducing selection bias and resulting in a relatively small sample size that did not allow us to evaluate bleeding events and/or a net clinical benefit outcome. However, the VTE-BLEED has previously been validated in 3 independent high-quality cohorts totaling over 17 000 patients 12, 13, 15 in which results were deemed to be sufficiently conclusive and validation of the score was therefore not part of the aims of the present analysis. Further, our results cannot be generalized High risk Low risk 10 0 to patients with provoked PE or those with DVT or treated with DOACs, although we do not anticipate relevant differences in the 2 latter patient categories.
In conclusion, the current analysis shows that, after stopping anticoagulant therapy, patients with a first unprovoked PE and a high risk of major bleeding by VTE-BLEED did not have a higher incidence of recurrent VTE than did patients in the VTE-BLEED low-risk category. These results support the appropriateness of the score for making management decisions on the optimal duration of anticoagulant therapy. Whereas long-term anticoagulant treatment has been suggested to be safe and appropriate in patients with unprovoked VTE in the VTE-BLEED low-risk category, further outcome studies should explore the optimal duration of anticoagulant therapy of VTE-BLEED high-risk patients. 
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